tetano
Editor, Senior Moderator
J Genet Eng Biotechnol
. 2022 Nov 4;20(1):155.
doi: 10.1186/s43141-022-00436-y.
Immunogenicity and effectiveness of a bivalent influenza A/H1N2 vaccine strain against seasonal human influenza A viruses in mice
Mina Nabil Kamel[SUP] #[/SUP][SUP] 1 [/SUP], Sara H Mahmoud[SUP] #[/SUP][SUP] 1 [/SUP], Yassmin Moatasim[SUP] #[/SUP][SUP] 1 [/SUP], Ahmed El Taweel[SUP] 1 [/SUP], Mahmoud Shehata[SUP] 1 [/SUP], Mohamed Refaat Shehata[SUP] 2 [/SUP], Elsayed Tarek AbdElSalam[SUP] 3 [/SUP], Mohamed A Ali[SUP] 4 [/SUP], Ahmed Mostafa[SUP] 5 [/SUP]
Affiliations
Abstract
Background: Recent studies and reports have documented the ability of the co-circulating seasonal influenza A/H1N1 (ancestor: 2009 pandemic H1N1) and A/H3N2 to exchange their genetic segments, generating a novel H1N2 strain in different geographical localities around the world with an ability to infect human. This raises concerns and triggers alarms to develop a multivalent vaccine that can protect against the documented H1- and H3-type human influenza A viruses (IAVs).
Results: Here, we generated a PR8-based vaccine strain that carries the HA gene segment from the contemporary H1N1 virus while the NA gene segment was derived from a currently circulating influenza A/H3N2 strain. A recombinant PR8-based H1N2 vaccine strain (rgH1N2), engineered by reassortment between influenza A/H1N1 and A/H3N2 to mimic the documented human influenza A/H1N2, was used for immunization to provoke immunogenicity and cross-antigenicity against the H1- and H3-type human IAVs and was evaluated for its immunogenicity and effectiveness in mice. Following challenge infection of rgH1N2-vaccinated mice with contemporary influenza A/H1N1 and A/H3N2, results revealed that rgH1N2-vaccinated mice showed less viral shedding, more survival, and less body weight loss compared to control unvaccinated groups and vaccinated mice with rgH1N1 and rgH3N2.
Conclusions: This study highlights the applicability of the PR8-based H1N2 vaccine strain to protect against seasonal IAVs and emphasizes the role of both surface proteins, HA and NA, to stimulate protective and neutralizing antibodies against circulating influenza A/H1N1 and A/H3N2 strains.
Keywords: Immunogenicity; Influenza; Influenza A/H1N1; Influenza A/H1N2; Influenza A/H3N2; Vaccine effectiveness.
. 2022 Nov 4;20(1):155.
doi: 10.1186/s43141-022-00436-y.
Immunogenicity and effectiveness of a bivalent influenza A/H1N2 vaccine strain against seasonal human influenza A viruses in mice
Mina Nabil Kamel[SUP] #[/SUP][SUP] 1 [/SUP], Sara H Mahmoud[SUP] #[/SUP][SUP] 1 [/SUP], Yassmin Moatasim[SUP] #[/SUP][SUP] 1 [/SUP], Ahmed El Taweel[SUP] 1 [/SUP], Mahmoud Shehata[SUP] 1 [/SUP], Mohamed Refaat Shehata[SUP] 2 [/SUP], Elsayed Tarek AbdElSalam[SUP] 3 [/SUP], Mohamed A Ali[SUP] 4 [/SUP], Ahmed Mostafa[SUP] 5 [/SUP]
Affiliations
- PMID: 36331680
- DOI: 10.1186/s43141-022-00436-y
Abstract
Background: Recent studies and reports have documented the ability of the co-circulating seasonal influenza A/H1N1 (ancestor: 2009 pandemic H1N1) and A/H3N2 to exchange their genetic segments, generating a novel H1N2 strain in different geographical localities around the world with an ability to infect human. This raises concerns and triggers alarms to develop a multivalent vaccine that can protect against the documented H1- and H3-type human influenza A viruses (IAVs).
Results: Here, we generated a PR8-based vaccine strain that carries the HA gene segment from the contemporary H1N1 virus while the NA gene segment was derived from a currently circulating influenza A/H3N2 strain. A recombinant PR8-based H1N2 vaccine strain (rgH1N2), engineered by reassortment between influenza A/H1N1 and A/H3N2 to mimic the documented human influenza A/H1N2, was used for immunization to provoke immunogenicity and cross-antigenicity against the H1- and H3-type human IAVs and was evaluated for its immunogenicity and effectiveness in mice. Following challenge infection of rgH1N2-vaccinated mice with contemporary influenza A/H1N1 and A/H3N2, results revealed that rgH1N2-vaccinated mice showed less viral shedding, more survival, and less body weight loss compared to control unvaccinated groups and vaccinated mice with rgH1N1 and rgH3N2.
Conclusions: This study highlights the applicability of the PR8-based H1N2 vaccine strain to protect against seasonal IAVs and emphasizes the role of both surface proteins, HA and NA, to stimulate protective and neutralizing antibodies against circulating influenza A/H1N1 and A/H3N2 strains.
Keywords: Immunogenicity; Influenza; Influenza A/H1N1; Influenza A/H1N2; Influenza A/H3N2; Vaccine effectiveness.